<DOC>
	<DOCNO>NCT00828529</DOCNO>
	<brief_summary>The purpose Phase I , open-label , randomize crossover trial investigate pharmacokinetic interaction steady-state lopinavir/ritonavir single-dose TMC207 healthy volunteer .</brief_summary>
	<brief_title>TMC207-TiDP13-C110 : Interaction Study With Lopinavir/Ritonavir Healthy Volunteer</brief_title>
	<detailed_description>TMC207 investigate treatment MDR-TB infection . This Phase I , open-label , randomize crossover trial healthy volunteer investigate potential interaction steady-state lopinavir/ritonavir ( LPV/rtv ) 400/100 mg twice daily single dose 400 mg TMC207 . The trial population consist 16 healthy volunteer . During 2 session , participant receive 2 treatment ( Treatments A B ) randomize order . This mean decided chance subject receive first treatment A , B first treatment B , A . In Treatment A , participant receive single dose TMC207 400 mg Day 1 . In Treatment B , participant receive LPV/rtv 400/100 mg twice daily Days 1 24 , Day 11 single dose TMC207 400 mg co-administered . The two single dos TMC207 administer 4 week apart . Consequently , Treatment B start 4 day completion Treatment A , Treatment A start 14 day completion Treatment B ( count day last PK sample collect ) . Pharmacokinetic profile 336 hour determine TMC207 N-monodesmethyl metabolite ( M2 ) administration TMC207 400 mg alone ( Day 1 Treatment A ) , combination steady-state LPV/rtv ( Day 11 Treatment B ) . Morning predose concentration lopinavir ritonavir determine several time point . Safety tolerability evaluate throughout trial . Day 1 Treatment A Day 11 Treatment B , 400 mg TMC207 ( 1 tablet ) take orally morning within 10 min . completion meal . Days 1 24 Treatment B , 2 tablet Lopinavir/Ritonavir ( LPV/rtv = 400 mg lopinavir 100 mg ritonavir ) take morning evening . When LPV/rtv administer alone , take without food . When co-administered simultaneously TMC207 , LPV/rtv intake within 10 min . completion meal .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Bedaquiline</mesh_term>
	<mesh_term>Diarylquinolines</mesh_term>
	<criteria>Nonsmoking smoke 10 cigarette , 2 cigar , 2 pipe per day least 3 month prior selection Body Mass Index 18.0 32.0 kg/m2 , extremes include Able comply protocol requirement Healthy basis physical examination , medical history , ECG , vital sign result blood biochemistry hematology test urinalysis carry screen Informed Consent Form sign voluntarily first trialrelated activity . A positive HIV1 HIV2 test Female , except postmenopausal since 2 year , posthysterectomy , postsurgical sterilization Hepatitis A , B , C infection Evidence current use illicit drug opioids abuse alcohol Currently active underlie disorder include gastrointestinal , cardiovascular , neurologic , psychiatric , metabolic , renal , hepatic , respiratory , inflammatory , infectious disease Any history significant skin disease allergy include allergy hypersensitivity excipients investigational medication administer trial Use concomitant medication , include overthecounter product dietary supplement , except ibuprofen paracetamol 3 day first dose trial medication Recent donation blood plasma participation clinical trial Subjects QTc prolongation clinically significant ECG abnormality family history Long QT Syndrome .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>TMC207-TiDP13-C110</keyword>
	<keyword>TMC207-C110</keyword>
	<keyword>TMC207</keyword>
	<keyword>Drug-drug interaction</keyword>
	<keyword>Tuberculosis</keyword>
	<keyword>HIV</keyword>
	<keyword>Kaletra</keyword>
	<keyword>Lopinavir</keyword>
	<keyword>Ritonavir</keyword>
	<keyword>Open-label</keyword>
	<keyword>HIV Infections</keyword>
</DOC>